China's ophthalmic refractive surgery market is experiencing significant technological upgrades. According to statistics released by the Chinese Medical Association's Ophthalmology Branch in 2023, the annual number of refractive surgeries in China has surpassed 2 million cases, with SMILE (Small Incision Lenticule Extraction) and ICL implantation accounting for over 60% combined, becoming the mainstream procedures for correcting myopia and astigmatism. The latest research from the Eye & ENT Hospital of Fudan University shows that for low-to-moderate myopia (≤800 degrees), SMILE achieves a postoperative uncorrected visual acuity of 1.0 in 96.2% of cases, while ICL achieves this in 94.8% of high myopia cases (>800 degrees), both demonstrating excellent outcomes.
This technological comparison is not a simple matter of superiority but rather a choice based on the patient's ocular conditions, visual needs, and lifestyle. SMILE uses a femtosecond laser to create a lenticule in the corneal stroma and extract it without creating a corneal flap; ICL involves implanting a foldable intraocular lens without cutting corneal tissue. The 2024 guidelines from the Chinese Medical Doctor Association's Ophthalmology Branch indicate that preoperative evaluation should cover 12 parameters, including corneal thickness, anterior chamber depth, and endothelial cell count, to determine the optimal indications.
Background and Significance
The evolution of refractive surgery technology in China, from PRK and LASIK to SMILE and ICL, reflects a shift from a one-size-fits-all approach to precision medicine. SMILE was introduced to China in 2011 and rapidly gained popularity due to its minimally invasive nature (incision of only 2-4 mm) and lower incidence of postoperative dry eye (approximately 5%, significantly reduced from LASIK's 20%). ICL, in use since 2006, has become the preferred option for patients with thin corneas or high myopia due to its reversibility and preservation of corneal biomechanical stability. In 2023, the National Medical Products Administration approved the new-generation ICL V4c model, whose central hole design simplifies the surgical procedure and reduces intraocular pressure risk, driving a 25% annual increase in implantations.
Significance for International Patients
For overseas patients, this technological comparison provides a clearer decision-making framework. SMILE is suitable for those with active lifestyles or high-risk occupations (such as athletes and firefighters) due to the absence of corneal flap dislocation risk; ICL is ideal for patients with insufficient corneal thickness (<480 micrometers) or myopia exceeding 1000 degrees. The 2024 report from the International Society of Refractive Surgery (ISRS) shows that China leads globally in ICL surgical volume, with over 200,000 procedures annually and a complication rate below 0.1%. Additionally, surgical costs in China are 40-60% lower than in Europe and the United States, with SMILE priced at approximately 15,000-20,000 RMB and ICL at 30,000-40,000 RMB, attracting a large number of patients from Southeast Asia and the Middle East.
How Meikangjia Can Help
Meikangjia, as a cross-border medical platform, provides comprehensive support for international patients. Our partner top-tier ophthalmic centers in China, such as Beijing Tongren Hospital and the Eye & ENT Hospital of Fudan University in Shanghai, are equipped with Zeiss VisuMax femtosecond laser systems and ICL-specific surgical equipment, with surgical teams having over 5,000 procedure experiences. Through the cost estimator tool, patients can obtain real-time detailed quotes covering surgery, preoperative examinations (such as corneal topography and wavefront aberration analysis), and postoperative follow-ups (at 1 day, 1 week, and 3 months). Our medical consultants recommend the most suitable procedure based on the patient's refractive error, corneal parameters, and occupational needs, and coordinate visa arrangements, translation services, and remote postoperative consultations to ensure continuity of care.
Related reading: Overview of Partner Hospitals in Shanghai